Director of Sales at a medtech company
What the role actually does in European medtech — who the buyer is, how the cycle runs, what seniority the market appoints, and where the hire comes from. Written from our own tracked dataset of European hard-tech companies and their commercial leadership.
What a Director of Sales does in medtech
A Director of Sales owns a region, segment or product line, and carries a target for it — a working leader who still sells. The title is the same as in software; the job is not.
In European medtech, the buyer is hospitals, surgeons, procurement groups and national reimbursement bodies. The sales cycle runs 12–36 months, gated by clinical evidence, CE/FDA approval and reimbursement coding. The unit of sale is a capital sale plus recurring consumables, or a per-procedure model.
Which means: no reimbursement, no market. Market access is not a support function here — it is the commercial strategy.
What they own: a named territory or segment target, and the account plans within it. Team: usually two to eight people, or none at all — many are player-coaches.
When the role gets created
Appointed when one person can no longer cover the territory or the segments diverge. The wider pattern is that this happens late. Of the European medtech companies whose leadership we have verified against what they publish themselves, around half have no commercial leader of any kind. The sector builds the technology first and the commercial function years later.
Watch the level. European medtech companies usually appoint their commercial leader at C-level (CCO/CRO), not at director. If you are hiring a Director of Sales, you are hiring below the level the market treats as the commercial leader — which normally means the role reports into a founder who is still running commercial themselves.
Seniority: what medtech actually appoints
Across the commercial seats we have evidenced in European medtech, the sector's centre of gravity sits at C-level (CCO/CRO). This is not a market that builds broad sales teams: it is a market that appoints one senior commercial figure, usually years after the first product works, and lets them build underneath.
The practical consequence for candidates: titles run senior for the size of company. A "Head of" in this sector is frequently the entire commercial function. The practical consequence for founders: appointing below the sector norm tends to mean the founder stays the de facto commercial leader.
Where the hire comes from
The pattern across European medtech is consistent, and it is the opposite of what software hiring would predict: commercial leaders here arrive from industry incumbents, not from other startups. The recurring feeders are the industrial groups, the semiconductor primes, the instrument makers and the large engineering conglomerates — the places where people learned to sell a physical system into a conservative buyer on a multi-year cycle.
Startup-to-startup moves are rare. When you are asking a customer to bet a production line, a launch window or a national programme on your technology, scar tissue beats hustle, and hiring committees in this sector know it.
What medtech companies hire the Director of Sales to fix
Clinical selling experience and a working knowledge of reimbursement pathways in each target country. That is the real hiring brief behind the job description, and it is why commercial leaders imported from software rarely last in this sector: they are hired for a motion (fast cycles, quarterly bookings, self-serve funnels) that does not exist here.
Open sales mandates in medtech today
Commercial mandates in European medtech open and close continuously, and the live set changes weekly. We track them daily from company boards.
Browse the live medtech roles →
Frequently asked
What does a Director of Sales at a medtech company actually do?
They owns a region, segment or product line, and carries a target for it — a working leader who still sells. In medtech specifically, that means selling to hospitals, surgeons, procurement groups and national reimbursement bodies, over a cycle of 12–36 months, gated by clinical evidence, CE/FDA approval and reimbursement coding. The unit of sale is a capital sale plus recurring consumables, or a per-procedure model. No reimbursement, no market. Market access is not a support function here — it is the commercial strategy.
When does a medtech company hire a Director of Sales?
Appointed when one person can no longer cover the territory or the segments diverge. It happens late. Of the European medtech companies whose leadership we have verified, around half have no commercial leader at all — the sector builds the technology first and the commercial function years afterwards.
Who gets hired into this role?
Almost always someone from an industry incumbent rather than another startup — the industrial groups, semiconductor primes, instrument makers and engineering conglomerates. Domain credibility with a technical, risk-averse buyer matters more than a track record of fast SaaS growth.
What makes this role different from the same title in software?
Clinical selling experience and a working knowledge of reimbursement pathways in each target country. The cycle runs 12–36 months, gated by clinical evidence, CE/FDA approval and reimbursement coding — long enough that a commercial leader hired from a SaaS background, where quarterly bookings are the metric, often fails against a calendar they cannot compress.
What seniority should this role be?
European medtech companies typically appoint their commercial leader at C-level (CCO/CRO) level. Hiring below that usually means the founder remains the real commercial leader, with the new hire executing rather than owning the number.
Related
The GTM Talent Tracker maps the commercial layer of European hard tech company by company — who has built a commercial function, who hasn’t, where their leaders were recruited from, and what is open now. Role-level, from public sources, updated every morning. See the tracker →